Uniphar PLC Navi acquisition not cleared by CCPC (9160J)
16 Dezembro 2022 - 4:00AM
UK Regulatory
TIDMUPR
RNS Number : 9160J
Uniphar PLC
16 December 2022
Navi acquisition not cleared by CCPC
Dublin, London | 16 December 2022: Uniphar plc today announces
that the Irish Competition and Consumer Protection Commission
("CCPC") has not cleared the proposed acquisition of
Irish-headquartered pharmacy services group Navi Group
("Navi").
Following the proposal to acquire Navi, which was announced on
23(rd) December 2021, both Uniphar and Navi have engaged
extensively with the CCPC and supported them in their review of the
proposed transaction. However, the transaction will now no longer
proceed to completion.
Navi has been a longstanding partner of Uniphar and both parties
will continue to work closely together to support our shared
customer base of independent community pharmacies.
For further details contact:
Uniphar +353 (0) 1 428 7777
Allan Smylie
------------------------------
Head of Strategy and IR investor.relations@Uniphar.ie
------------------------------
Davy (Joint Corporate Broker, Nominated
Adviser and Euronext Growth Listing
Sponsor) +353 (0) 1 679 6363
------------------------------
Barry Murphy
------------------------------
Niall Gilchrist
------------------------------
Lauren O'Sullivan
------------------------------
RBC Capital Markets (Joint Corporate
Broker) +44 (0) 20 7653 4000
------------------------------
Jonathan Hardy
------------------------------
Jamil Miah
------------------------------
Stifel Nicolaus Europe Limited (Joint
Corporate Broker) +44 (0) 20 7710 7600
------------------------------
Matt Blawat
------------------------------
Ben Maddison
------------------------------
Francis North
------------------------------
Q4 PR +353 (0) 1 475 1444
or
------------------------------
(Public Relations Adviser to Uniphar) +353 87 235 6461
------------------------------
Iarla Mongey
------------------------------
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an
international diversified healthcare services business servicing
the requirements of more than 200 multinational pharmaceutical and
medical technology manufacturers across three divisions -
Commercial & Clinical, Product Access and Supply Chain &
Retail. The Group is active in Ireland, the UK, Europe, the US and
Australia.
The Company's vision is to improve patient access to
pharmaco-medical products and treatments by enhancing connectivity
between manufacturers and healthcare stakeholders. Uniphar
represents a strong combination of scale, growth, and
profitability.
Commercial & Clinical
In Commercial & Clinical, the Group provides outsourced
sales, marketing & distribution solutions to multinational
pharmaceutical and medical device manufacturers. Active in Ireland,
the UK, Benelux, the Nordics, Germany and the US, the Group is
growing with its clients to provide pan-European solutions, with a
targeted service offering in the US. Uniphar has built fully
integrated digitally enabled customer centric solutions that are
supported by our highly experienced and clinically trained teams,
leveraging our digital technology and insights which allows us to
deliver consistently exceptional outcomes for our clients.
Product Access
In Product Access, the Group is growing two distinct service
offerings: 1) "On Demand", which are pharmacy led solutions for
sourcing and supplying unlicensed medicines to meet the needs of
both retail and hospital pharmacists; and 2) "Exclusive Access",
which are manufacturer led solutions for controlling the release of
speciality medicines for specifically approved patient populations
in agreed markets. The Group currently delivers product access
solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with c. 53%
market share in the wholesale/hospital market, supported by a
network of 381 owned, franchised and symbol group pharmacies. The
business supports the diverse customer base through the provision
of strong service levels coupled with innovative commercial
initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and
infrastructure are also utilised for the benefit of the Commercial
& Clinical and Product Access divisions
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQGPGCWPUPPGRA
(END) Dow Jones Newswires
December 16, 2022 02:00 ET (07:00 GMT)
Uniphar (LSE:UPR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Uniphar (LSE:UPR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
